At the same time, Biofarm recorded an EBITDA of RON92 million, up 12% compared to 2021.
“One of our main objectives is to constantly increase turnover by developing and launching new products. In 2022, through sustained investment, we launched 18 new products in categories such as Pain Management, Immunity & Well-being, Bloating and strengthened our position in the local pharmaceutical market. With the new production facility in which we have invested over EUR44 million we aim to grow and develop a competitive product portfolio based on the real needs of the market, both locally and internationally, said Catalin Vicol, CEO of Biofarm.
Biofarm is one of the leading players in the local pharmaceuticals industry, in the category of Consumer Healthcare (CHC), ranking third in 2022 by volume.
In September 2022, the company said it reached investments worth over EUR44 million at the plant inaugurated in capital Bucharest in 2021, which is the largest greenfield investment in the pharmaceuticals sector in Romania.
BIO shares have gained 8.44% since the beginning of 2023, amid total deal worth RON671,036.
The company, with a market capitalization of RON662 million, is 51.5% held by SIF Muntenia and 36.7% by SIF Banat-Crisana.